Optimization of the antitumor treatment with crotamine through oral route

• Grant number: 18/03102-2
• Support Opportunities: Scholarships in Brazil - Master
• Start date: June 01, 2018
• End date: February 29, 2020
• Field of knowledge: Biological Sciences - Pharmacology - Biochemical and Molecular Pharmacology
• Agreement: Coordination of Improvement of Higher Education Personnel (CAPES)
• Principal Investigator: Mirian Akemi Furuie Hayashi
• Grantee: Lucas de Carvalho Porta
• Host Institution: Instituto Nacional de Farmacologia (INFAR). Universidade Federal de São Paulo (UNIFESP). Campus São Paulo. São Paulo , SP, Brazil

Abstract

Crotamine was first described in the 1970s, and was characterized mainly by its characteristic hind limb immobilization of rodents, observed only in the case of high dose administration. Recently, our group described other pharmacological and therapeutically useful effects regarding the use of reduced doses of crotamine, including cytotoxic effect with preference for proliferatively active cells (allowing its use as antitumor agent), ability to cross cell membranes and transporting other molecules into cells (use as delivery vector of therapeutic genes), and activity in animal metabolism, among others. Crotamine treatment of animal models with subcutaneous murine melanoma, administered either orally or intraperitoneally, showed an important remission of tumor growth and survival of the treated animal. The present work proposes the administration of crotamine associated with nanoparticles, since they are capable of allowing the controlled and prolonged release of compounds in the animal organism, aiming the improve of antitumor treatment with oral crotamine. The effect of this formulation on the tumor growth remission will be evaluated in comparison to the effect of non-associated pure crotamine, following the protocols and analyzes adopted in studies conducted so far in our laboratory. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

PORTA, LUCAS C.; CAMPEIRO, JOANA D.; PAPA, GIOVANNA B.; OLIVEIRA, EDUARDO B.; GODINHO, ROSELY O.; RODRIGUES, TIAGO; HAYASHI, MIRIAN A. F.. In vivo effects of the association of the psychoactive phenotiazine thioridazine on antitumor activity and hind limb paralysis induced by the native polypeptide crotamine. Toxicon, v. 185, p. 64-71, OCT 15 2020. (13/13392-4, 18/03102-2, 17/02413-1, 18/00014-5, 18/21381-6)

ALTAF-UL-AMIN, MD.; HIROSE, KAZUHISA; NANI, JOAO V.; PORTA, LUCAS C.; TASIC, LJUBICA; HOSSAIN, SHAIKH FARHAD; HUANG, MING; ONO, NAOAKI; HAYASHI, MIRIAN A. F.; KANAYA, SHIGEHIKO. A system biology approach based on metabolic biomarkers and protein-protein interactions for identifying pathways underlying schizophrenia and bipolar disorder. SCIENTIFIC REPORTS, v. 11, n. 1, JUL 14 2021. (20/01107-7, 18/03102-2, 19/09207-3, 19/13112-8)